Passive immunization as prophylaxis: When and where will this work

Current Opinion in Pharmacology

Volumn 3, Issue 5, 2003, Pages 486-496

  Dunman, Paul M ^a   Nesin, Mirjana ^b  

^a PFIZER INC   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BACTERIAL TOXIN; BAYHEP B; BSYX A110; CELL SURFACE IMMUNOGLOBULIN; CHICKENPOX VACCINE; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HUMAN IMMUNOGLOBULIN; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOMODULATING AGENT; INACTIVATED VACCINE; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; MEASLES MUMPS RUBELLA VACCINE; MONOCLONAL ANTIBODY; PALIVIZUMAB; PLACEBO; POLYCLONAL ANTIBODY; RECOMBINANT ANTIBODY; RECOMBINANT GROWTH FACTOR; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALGANCICLOVIR;

ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBODY PRODUCTION; ANTIBODY TITER; BONE MARROW TOXICITY; CHEMOTHERAPY; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG COMPETITION; DRUG EFFICACY; DRUG ISOLATION; DRUG RESEARCH; DRUG SPECIFICITY; EDEMA; EXPOSURE; FEVER; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGAMMAGLOBULINEMIA; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; META ANALYSIS; NEPHROTOXICITY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL VACCINES; CLINICAL TRIALS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; VIRUS DISEASES;

EID: 0141535259     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2003.05.005     Document Type: Review

References (83)

1. Wesselhoeft C. Treatment of scarlet fever and diphtheria Med Clin North Am 19 1936 1389-1407
2. Andresen I. Kovarik J.M. Spycher M. Bolli R. Product equivalence study comparing the tolerability, pharmacokinetics, and pharmacodynamics of various human immunoglobulin-G formulations J Clin Pharmacol 40 2000 722-730
3. Schwartz S.A. Intravenous immunoglobulin treatment of immunodeficiency disorders Pediatr Clin North Am 47 2000 1355-1369
4. Sacher R.A. Intravenous immunoglobulin consensus statement J Allergy Clin Immunol 108 2001 S139-S146
5. Keller M.A. Stiehm E.R. Passive immunity in prevention and treatment of infectious diseases Clin Microbiol Rev 13 2000 602-614
6. Hamdan A. Green P. Mendelson E. Kramer M.R. Pitlik S. Weinberger M. Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis Transpl Infect Dis 4 2002 160-162
7. Koduri P.R. Kumapley R. Valladares J. Teter C. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin - a report of eight patients Am J Hematol 61 1999 16-20
8. The Intravenous Immunoglobulin Collaborative Study Group: Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 1992, 327:234-240.
9. Friedrich I. Silber R.E. Baumann B. Fischer C. Holzheimer R.G. IgM-enriched immunoglobulin preparation for immunoprophylaxis in cardiac surgery Eur J Med Res 7 2002 544-549
10. Stoll B.J. Hansen N. Fanaroff A.A. Wright L.L. Carlo W.A. Ehrenkranz R.A. Lemons J.A. Donovan E.F. Stark A.R. Tyson J.E. et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network Pediatrics 110 2002 285-291
11. Ohlsson A, Lacy JB: Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev 2001, 2:CD000361.
12. Jenson H.B. Pollock B.H. Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis Pediatrics 99 1997 E2
13. Lamari F. Karamanos N.K. Papadopoulou-Alataki E. Kanakoudi-Tsakalidou F. Dimitracopoulos G. Anastassiou E.D. Monitoring of two intravenous immunoglobulin. Preparations for immunoglobulin G subclasses and specific antibodies to bacterial surface antigens and relation with their levels in treated immunodeficient patients J Pharm Biomed Anal 22 2000 1029-1036
14. Englund J.A. Glezen W.P. Passive immunization for the prevention of otitis media Vaccine 19 2000 S116-S121
15. Lamothe F. D'Amico P. Ghosn P. Tremblay C. Braidy J. Patenaude J.V. Clinical usefulness of intravenous human immunoglobulins in invasive group A Streptococcal infections: case report and review Clin Infect Dis 21 1995 1469-1470
16. Schrag S.J. Zell E.R. Lynfield R. Roome A. Arnold K.E. Craig A.S. Harrison L.H. Reingold A. Stefonek K. Smith G. et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates N Engl J Med 347 2002 233-239
17. Regan J.A. Klebanoff M.A. Nugent R.P. The epidemiology of group B streptococcal colonization in pregnancy. Vaginal Infections and Prematurity Study Group Obstet Gynecol 77 1991 604-610
18. Paoletti L.C. Potency of clinical group B streptococcal conjugate vaccines Vaccine 19 2001 2118-2126
19. Beninati C. Oggioni M. Mancuso G. Midiri A. Polonelli L. Pozzi G. Teti G. Anti-idiotypic vaccination against group B streptococci Int Rev Immunol 20 2001 263-273
20. Barry W. Hudgins L. Donta S.T. Pesanti E.L. Intravenous immunoglobulin therapy for toxic shock syndrome J Am Med Assoc 267 1992 3315-3316
21. Higuchi S. Awata H. Nunoi H. Tsuchiya H. Naoe H. Igarashi H. Matsuda I. A family of selective immunodeficiency with normal immunoglobulins: possible autosomal dominant inheritance Eur J Pediatr 153 1994 328-332
22. Fischer G.W. Cieslak T.J. Wilson S.R. Weisman L.E. Hemming V.G. Opsonic antibodies to Staphylococcus epidermidis: in vitro and in vivo studies using human intravenous immune globulin J Infect Dis 169 1994 324-329
23. Weisman LE, Schuman RF, Lukomska E, Stinson JR, Parks O, Fischer GW: Effectivness and pharmacokinetics of an anti-lipoteichoic acid humanized mouse chimeric monoclonal antibodies. In Pediatric Academic Society, Baltimore MD, 2001:301A.
24. Weisman LE, Mandy GT, Garcia-Prats JA, Nesin M, Schneider JH, Johnson KE, Mond J, Thachkray H, Adams K, Fischer GW: Safety and pharmacokinetics of a human chimeric anti-staphylococcal monoclonal antibody for prevention of coagulase negative staphylococcal infection in very low birth weight infants: preliminary report. In Pediatric Academic Society, Seattle WA, 2003:315A.
25. Bloom BT, Kueser TJ, Oelberg DG, Bifano EM, White RD, Schelonka RL, Pearlman SA, Hetherington SV: A phase I, multicenter study of safety and tolerance of a donor-selected Staphylococcal immune globulin in very low birth weight infants. In Pediatric Academy Society, Seattle WA, 2003:316A.
26. Baumgartner J.D. Glauser M.P. McCutchan J.A. Ziegler E.J. van Melle G. Klauber M.R. Vogt M. Muehlen E. Luethy R. Chiolero R. et al. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid Lancet 2 1985 59-63
27. The HA-1A monoclonal antibody for gram-negative sepsis. N Engl J Med 1991, 325:279-283.
28. Debroy C. Yealy J. Wilson R.A. Bhan M.K. Kumar R. Antibodies raised against the outer membrane protein interrupt adherence of enteroaggregative Escherichia coli Infect Immun 63 1995 2873-2879
29. Lun M.T. Raponi G. Amatucci A.M. Natali P.G. Fraioli R. Mancini C. Characterisation and protective capacity of monoclonal antibodies elicited in mice against protein epitopes of antibiotic-exposed Escherichia coli J Med Microbiol 46 1997 122-128
30. Raponi G. Ghezzi M.C. Lun M.T. Bigotti G. Natali P.G. Mancini C. Protective features of monoclonal antibodies to Escherichia coli during experimental infection of mice with homologous and heterologous serotypes of E. coli J Med Microbiol 49 2000 253-260
31. Ziegler E.J. Fisher C.J. Jr. Sprung C.L. Straube R.C. Sadoff J.C. Foulke G.E. Wortel C.H. Fink M.P. Dellinger R.P. Teng N.N. et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group N Engl J Med 324 1991 429-436
32. Mukherjee J. Chios K. Fishwild D. Hudson D. O'Donnell S. Rich S.M. Donohue-Rolfe A. Tzipori S. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection Infect Immun 70 2002 612-619
33. Corbett CR, Kooi C, Woods DE, Sokol PA: Passive immunotherapy of experimental Pseudomonas aeruginosa lung infections with monoclonal antibodies generated to a P. aeruginosa elastase peptide. In 42nd Interscience Conference of Antimicrobial Agents and Chemotherapy, San Diego CA, 2002:46.
34. Zimmerman R.K. Middleton D.B. Smith N.J. Vaccines for persons at high risk due to medical conditions, occupation, environment, or lifestyle, 2003 J Fam Pract 52 2003 S22-S35
35. Weisman L.E. Current respiratory syncytial virus prevention strategies in high-risk infants Pediatr Int 44 2002 475-480
36. Sorrentino M. Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group Pediatr Infect Dis J 19 2000 1068-1071
37. Piedimonte G. King K.A. Holmgren N.L. Bertrand P.J. Rodriguez M.M. Hirsch R.L. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways Pediatr Res 47 2000 351-356
38. Meissner H.C. Welliver R.C. Chartrand S.A. Law B.J. Weisman L.E. Dorkin H.L. Rodriguez W.J. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion Pediatr Infect Dis J 18 1999 223-231
39. Dix R.D. Cray C. Cousins S.W. Antibody alone does not prevent experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency (MAIDS) Ophthalmic Res 29 1997 381-392
40. Sissons J.G. Carmichael A.J. Clinical aspects and management of cytomegalovirus infection J Infect 44 2002 78-83
41. Masur H. Kaplan J.E. Holmes K.K. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America Ann Intern Med 137 2002 435-478
42. Vittecoq D. Mattlinger B. Barre-Sinoussi F. Courouce A.M. Rouzioux C. Doinel C. Bary M. Viard J.P. Bach J.F. Rouger P. et al. Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma J Infect Dis 165 1992 364-368
43. Xu W. Hofmann-Lehmann R. McClure H.M. Ruprecht R.M. Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV Vaccine 20 2002 1956-1960
44. Ferrantelli F. Hofmann-Lehmann R. Rasmussen R.A. Wang T. Xu W. Li P.L. Montefiori D.C. Cavacini L.A. Katinger H. Stiegler G. et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques AIDS 17 2003 301-309
45. Abstract of section scientific presentations. American Academy of Pediatrics 1997 annual meeting. October 31-November 4, 1997, New Orleans, Louisiana. Pediatrics 1997, 100:423-584.
46. Piazza M. Sagliocca L. Tosone G. Guadagnino V. Stazi M.A. Orlando R. Borgia G. Rosa D. Abrignani S. Palumbo F. et al. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial Arch Intern Med 157 1997 1537-1544
47. Feray C. Caccamo L. Alexander G.J. Ducot B. Gugenheim J. Casanovas T. Loinaz C. Gigou M. Burra P. Barkholt L. et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group Gastroenterology 117 1999 619-625
48. Sakurai T. Misawa E. Tanaka-Douzono M. Hagesita H. Nomaguchi K. Tetsuya K. Suzu S. Yamada M. Hayasawa H. Motoyoshi K. Effect of coadministration of M-CSF and IFN-alpha on NK1.1+ cells in mice J Interferon Cytokine Res 22 2002 701-708
49. Dale D.C. Colony-stimulating factors for the management of neutropenia in cancer patients Drugs 62 Suppl 1 2002 1-15
50. Garcia-Carbonero R. Mayordomo J.I. Tornamira M.V. Lopez-Brea M. Rueda A. Guillem V. Arcediano A. Yubero A. Ribera F. Gomez C. et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial J Natl Cancer Inst 93 2001 31-38
51. Bohlius J, Reiser M, Schwarzer G, Engert A: Granulopoiesis-stimulating factors in the prevention for adverse effects in the therapeutic treatment of malignant lymphoma. Cochrane Database Syst Rev 2002:CD003189.
52. Berghmans T. Paesmans M. Lafitte J.J. Mascaux C. Meert A.P. Jacquy C. Burniat A. Steels E. Vallot F. Sculier J.P. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis Support Care Cancer 10 2002 181-188
53. Welte K. Dale D. Pathophysiology and treatment of severe chronic neutropenia Ann Hematol 72 1996 158-165
54. Freedman M.H. Bonilla M.A. Fier C. Bolyard A.A. Scarlata D. Boxer L.A. Brown S. Cham B. Kannourakis G. Kinsey S.E. et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy Blood 96 2000 429-436
55. Criteria for use of sargramostim (granulocyte-macrophage colony-stimulating factor). Clin Pharm 1991, 10:947-949.
56. Angel J.B. High K. Rhame F. Brand D. Whitmore J.B. Agosti J.M. Gilbert M.J. Deresinski S. Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group AIDS 14 2000 387-395
57. Carreno V. Martin J. Pardo M. Brotons A. Anchia P. Navas S. Fernandez M. Arocena C. Quiroga J.A. Randomized controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor for the treatment of chronic hepatitis C Cytokine 12 2000 165-170
58. Ahmad A. Laborada G. Bussel J. Nesin M. Comparison of recombinant granulocyte colony-stimulating factor, recombinant human granulocyte-macrophage colony-stimulating factor and placebo for treatment of septic preterm infants Pediatr Infect Dis J 21 2002 1061-1065
59. Sasaki E. Tashiro T. Kuroki M. Seki M. Miyazaki Y. Maesaki S. Tomono K. Kadota J. Kohno S. Effects of macrophage colony-stimulating factor (M-CSF) on anti-fungal activity of mononuclear phagocytes against Trichosporon asahii Clin Exp Immunol 119 2000 293-298
60. Schaison G. Eden O.B. Henze G. Kamps W.A. Locatelli F. Ninane J. Ortega J. Riikonen P. Wagner H.P. Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel Eur J Pediatr 157 1998 955-966
61. Bernstein H.M. Pollock B.H. Calhoun D.A. Christensen R.D. Administration of recombinant granulocyte colony-stimulating factor to neonates with septicemia: A meta-analysis J Pediatr 138 2001 917-920
62. Cairo M.S. Agosti J. Ellis R. Laver J.J. Puppala B. deLemos R. Givner L. Nesin M. Wheeler J.G. Seth T. et al. A randomized, double-blind, placebo-controlled trial of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor to reduce nosocomial infections in very low birth weight neonates J Pediatr 134 1999 64-70
63. Miura E. Procianoy R.S. Bittar C. Miura C.S. Miura M.S. Mello C. Christensen R.D. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis Pediatrics 107 2001 30-35
64. Remick D.G. Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr Pharm Des 9 2003 75-82
65. Manns B.J. Lee H. Doig C.J. Johnson D. Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis N Engl J Med 347 2002 993-1000
66. Criscione L.G. St Clair E.W. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases Curr Opin Rheumatol 14 2002 204-211
67. Wang Y.S. Youngster S. Grace M. Bausch J. Bordens R. Wyss D.F. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications Adv Drug Deliv Rev 54 2002 547-570
68. Demirturk N. Usluer G. Ozgunes I. Colak H. Kartal E.D. Dincer S. Comparison of different treatment combinations for chronic hepatitis B infection J Chemother 14 2002 285-289
69. Bolinger A.M. Taeubel M.A. Recombinant interferon gamma for treatment of chronic granulomatous disease and other disorders Clin Pharm 11 1992 834-850
70. Kole L. Das L. Das P.K. Synergistic effect of interferon-gamma and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis J Infect Dis 180 1999 811-820
71. Saulsbury F.T. Successful treatment of aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease Clin Infect Dis 32 2001 E137-E139
72. Kahlke V. Dohm C. Mees T. Brotzmann K. Schreiber S. Schroder J. Early interleukin-10 treatment improves survival and enhances immune function only in males after hemorrhage and subsequent sepsis Shock 18 2002 24-28
73. Mountzouros K.T. Belanger K.A. Howell A.P. Bixler G.S. Jr. Madore D.V. A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model Infect Immun 70 2002 6576-6582
74. de Hennezel L. Debarre S. Ramisse F. Delamanche S. Harf A. Alonso J.M. Calvet J.H. Plethysmography for the assessment of pneumococcal pneumonia and passive immunotherapy in a mouse model Eur Respir J 17 2001 94-99
75. Preston M.J. Gerceker A.A. Reff M.E. Pier G.B. Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide Infect Immun 66 1998 4137-4142
76. Phillips N.C. Gagne L. Ivanoff N. Riveau G. Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens Vaccine 14 1996 898-904
77. Han Y. Morrison R.P. Cutler J.E. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection Infect Immun 66 1998 5771-5776
78. Casadevall A. Cleare W. Feldmesser M. Glatman-Freedman A. Goldman D.L. Kozel T.R. Lendvai N. Mukherjee J. Pirofski L.A. Rivera J. et al. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies Antimicrob Agents Chemother 42 1998 1437-1446
79. Krasniaskii V.P. Gradoboev V.N. Borisevich I.V. Potryvaeva N.V. Lebedinskaia E.V. Chernikova N.K. Timan'kova G.D. [Development and study of immunoglobulins against Lassa fever] Vopr Virusol 42 1997 71-74
80. De Logu A. Williamson R.A. Rozenshteyn R. Ramiro-Ibanez F. Simpson C.D. Burton D.R. Sanna P.P. Characterization of a type-common human recombinant monoclonal antibody to herpes simplex virus with high therapeutic potential J Clin Microbiol 36 1998 3198-3204
81. Gigliotti F. Haidaris C.G. Wright T.W. Harmsen A.G. Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia Infect Immun 70 2002 1069-1074
82. Casadevall A. Scharff M.D. Return to the past: the case for antibody-based therapies in infectious diseases Clin Infect Dis 21 1995 150-161
83. Grabestain JD: ImmunoFacts, Vaccines and Immunologic Drugs. St. Louis: Wolters Kluwer; 2002.